Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BHT-3009: Phase IIb data

In a 12-month, double-blind, international Phase IIb trial in 289 relapsing remitting MS patients, 0.5 and 1.5 mg monthly intramuscular injections

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE